
Park Medi World Q1 Results FY27: PAT at Rs 82.5 Cr for June 2026 Quarter
Park Medi World Q1 FY27: PAT Rs 82.5 Cr (+42.30% YoY) | Revenue Rs 475.7 Cr (+19.30% YoY) | EBITDA margin 26.5%. Reported 9:43 AM IST, 3 August 2026.
Updated: 3 Aug 2026 • 4:15 pm
Posted by:

The Park Medi World Q1 results FY27 show revenue of Rs 475.7 Cr for the quarter ended 30 June 2026, +19.30% year on year from Rs 398.9 Cr in Q1 FY26, as Park Medi World reported its June quarter numbers at 9:43 AM IST on 3 August 2026. Park Medi World posted net profit of Rs 82.5 Cr for the quarter, against Rs 58 Cr in Q1 FY26, a change of +42.30%.
India's healthcare sector is in a structural multi-year upcycle, driven by rising insurance penetration, government schemes expanding hospital access to Tier-2 and Tier-3 cities, and growing chronic disease management demand. Hospitals that can sustain occupancy above 70% and hold Average Revenue Per Occupied Bed (ARPOB) steady are typically rewarded with operating efficiency gains flowing through to the bottom line. Against that backdrop, the Park Medi World Q1 results FY27 give investors the first hard data point for FY27. This article breaks down what happened at the revenue, operating, and net profit line, what the numbers mean for the full year, and what questions investors should be asking before making any portfolio decision.
Click Here – Get Free Investment Predictions
Park Medi World Q1 Results FY27 Financial Highlights
All figures below are as reported by Park Medi World and sourced from the Q1 FY27 results announcement. Revenue figures are in Rs Crore (3 August 2026).
| Metric | Q1 FY27 (Jun 2026) | Q1 FY26 (Jun 2025) | YoY Change |
|---|---|---|---|
| Revenue | Rs 475.7 Cr | Rs 398.9 Cr | +19.30% |
| EBITDA | Rs 126.1 Cr | Rs 104.9 Cr | +20.20% |
| EBITDA Margin | 26.5% | 26.3% | +0.2 pts |
| PAT | Rs 82.5 Cr | Rs 58 Cr | +42.30% |
Park Medi World Q1 FY27 Performance Analysis
Revenue came in at Rs 475.7 Cr for the June 2026 quarter, up +19.30% from Rs 398.9 Cr in Q1 FY26. The pace is moderate but consistent, the kind of compounding that, if sustained, translates into meaningful earnings growth over a full financial year.
EBITDA grew +20.20% to Rs 126.1 Cr at 26.5% of revenue, outpacing the revenue growth rate and pointing to operating efficiency gains working in the company's favour this quarter. Margin held broadly steady at 26.5% against 26.3% a year ago. Cost discipline or a higher-margin product mix is the most likely explanation, and management commentary will clarify which.
The bottom line was the cleanest positive in the release. Park Medi World posted net profit (PAT) of Rs 82.5 Cr for the quarter, up +42.30% from Rs 58 Cr in Q1 FY26. The combination of revenue growth and margin resilience is translating into a meaningfully higher earnings figure, the outcome investors were hoping to see.
Check the Univest Screener for Live Data
Park Medi World Q1 FY27: Key Business Factors
1. Revenue: What Drove the Quarter
Park Medi World has been investing in expansion, whether in hospital beds, product launches, branch network, or distribution reach, and this quarter's revenue figure of Rs 475.7 Cr is the quantitative outcome of that investment. The +19.30% year on year growth from Rs 398.9 Cr in Q1 FY26 needs to be read alongside capacity utilisation and realisation trends to fully understand its quality. High revenue growth driven by volume is typically more durable than pricing-led growth, and vice versa. Until management provides the breakdown, the aggregate figure is the best available data. Investors should check the investor presentation, usually released alongside the results or in a 24-hour window, for this split.
2. EBITDA and Margins: The Operating Health Check
EBITDA margin came in at 26.5%, broadly stable versus 26.3% in Q1 FY26 , a 0.2 percentage point movement either way. Margin stability in the broader market is an acceptable outcome, particularly in a quarter where input cost movements, demand cyclicality and competitive intensity can push costs higher. That said, flat margins over multiple quarters would signal that the business is not generating the operating efficiency gains that investors typically expect at this stage of revenue growth.
3. PAT: What the Bottom Line Tells You
Park Medi World reported net profit of Rs 82.5 Cr for the quarter against Rs 58 Cr a year earlier. The net profit is the number that ultimately flows through to earnings per share (EPS) and determines the P/E multiple at which the stock trades. A +42.30% year on year improvement in this line is the most positive element of the quarterly results from a valuation standpoint. Analysts will now update their full-year FY27 earnings estimates based on this Q1 run rate and any guidance that management provides alongside the results.
Park Medi World Q1 FY27 Results vs Expectations
Analyst estimates for the Park Medi World Q1 results FY27 varied ahead of the announcement. The actual revenue of Rs 475.7 Cr and net profit of Rs 82.5 Cr now set the benchmark against which FY27 consensus estimates will be revised. When a company beats on revenue and earnings simultaneously, the first trading session typically sees a positive price reaction as short sellers cover and institutional buyers step in. A miss on both is the reverse. A mixed print, beating on one line and missing on another, is harder to read and usually means the stock stays range-bound until the conference call provides clarity. Investors can track how Park Medi World is trading on the Univest Screener alongside analyst verdict updates after this result.
Dividend Update
Specific dividend information was not confirmed as part of this results snapshot. Most companies declare their dividend at the annual board meeting rather than the Q1 result. Investors tracking Park Medi World for its dividend yield should check the official NSE or BSE exchange filing, the company's investor relations page, or the Univest Screener for the latest record date and payout details.
Park Medi World Outlook After the Q1 FY27 Results
For Park Medi World specifically, the Q1 FY27 trends point to growth in revenue and improvement in the bottom line. Whether FY27 ends up as a year of acceleration, consolidation, or pressure depends largely on two variables: whether the growth in revenue sustains through Q2-Q4, and whether margin trends improve, stabilise, or deteriorate relative to this quarter's print. Management guidance, either in a formal earnings call or through an investor presentation, will be the single most important datapoint for updating FY27 forecasts.
The Q1 FY27 print gives investors a base to work from, but one quarter is rarely enough to conclude a trend. The key follow-up question for Park Medi World is whether the Q1 performance was driven by seasonal tailwinds or something more durable. Q2 FY27 results, due around October 2026, will be the first test of that. Investors should also watch for any corporate actions, debt announcements, or management changes in the interim.
Is Park Medi World a Good Buy After the Q1 FY27 Results?
The question investors most want answered after any quarterly result is whether it changes the investment thesis. For Park Medi World, the Park Medi World Q1 results FY27 show revenue of Rs 475.7 Cr, EBITDA of Rs 126.1 Cr, and net profit of Rs 82.5 Cr. Whether these numbers are 'good' depends on the price the stock is trading at, the FY27 full-year earnings estimate, and whether this Q1 run-rate is sustainable for the remaining three quarters. Investors should check the P/E, P/B, and EV/EBITDA multiples on the Univest Screener against sector peers before deciding. This article is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment advisor (Univest is SEBI RA INH000013776) before making any investment decision.
Park Medi World Share Price After the Q1 Results
Live price data for Park Medi World was not part of the results snapshot, but the stock typically reacts to Q1 results in the trading session following the announcement. Investors should check the live quote, the 52 week high and low, and technical support and resistance levels on the Univest Screener to contextualise the post-result price move before taking any action. A short-term price move immediately after results is often driven by event-driven traders rather than fundamental investors, and can reverse within the first few sessions.
Download the Univest iOS App or Univest Android App to track Park Medi World live share price and upcoming quarterly results.
Key Risks Investors Should Track
Before acting on the Park Medi World Q1 results FY27, investors should weigh these risks carefully.
1. Sector and Margin Risk
Park Medi World operates in the broader market, which is exposed to input cost movements, demand cyclicality and competitive intensity. A reversal in the trends visible in the Q1 FY27 numbers, particularly on the margin front, could put the full-year FY27 earnings estimate at risk and weigh on the stock.
2. Single-Quarter Noise vs Trend
Quarterly results can be distorted by working capital cycles, timing of receivables, or one-off costs and reversals. The Q1 FY27 print should be read alongside Q2 trends before drawing conclusions about the underlying trajectory of the business.
3. Macro and External Risk
Broader macro factors, RBI rate decisions, INR/USD movements, global commodity prices, and rural versus urban demand splits, can shift the business environment in the broader market faster than company-level actions can compensate for.
Conclusion
The Park Medi World Q1 results FY27 show revenue of Rs 475.7 Cr (+19.30% year on year) and net profit of Rs 82.5 Cr (versus Rs 58 Cr in Q1 FY26). EBITDA came in at Rs 126.1 Cr with a 26.5% margin. Revenue growth and a stronger bottom line were the two key themes of the quarter. Investors tracking Park Medi World should use this result as the Q1 FY27 baseline and watch Q2 FY27 results, due around October 2026, as the first real test of whether these trends are durable. Always consult a SEBI-registered advisor before acting on any quarterly result.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Park Medi World Q1 Results FY27
What were Park Medi World's Q1 FY27 results?
Ans. Park Medi World reported revenue of Rs 475.7 Cr for Q1 FY27 (quarter ended 30 June 2026), up +19.30% year on year from Rs 398.9 Cr in Q1 FY26. PAT came in at Rs 82.5 Cr, compared with Rs 58 Cr a year ago, a change of +42.30%.
What is the PAT in Park Medi World Q1 results FY27?
Ans. Park Medi World reported net profit of Rs 82.5 Cr for Q1 FY27, versus Rs 58 Cr in Q1 FY26. The change was +42.30%.
What was Park Medi World's revenue in Q1 FY27?
Ans. Park Medi World reported revenue of Rs 475.7 Cr for the June 2026 quarter, a change of +19.30% from Rs 398.9 Cr in Q1 FY26.
What was the EBITDA in Park Medi World Q1 FY27 results?
Ans. EBITDA for the quarter was Rs 126.1 Cr, up +20.20% from Rs 104.9 Cr in Q1 FY26. EBITDA margin was 26.5%.
When did Park Medi World announce Q1 FY27 results?
Ans. Park Medi World announced its Q1 FY27 results at 9:43 AM IST on 3 August 2026, for the quarter ended 30 June 2026. Investors should confirm the exact board meeting date and the results filing date from the official NSE or BSE announcement.
What is the outlook for Park Medi World after the Q1 FY27 results?
Ans. Following the Q1 FY27 results, analysts will update FY27 estimates for Park Medi World based on the quarterly run rate. Key things to watch: whether the growth in revenue continues into Q2 FY27, the trajectory of margins, and management guidance in the earnings call.
Is Park Medi World a good investment after Q1 FY27 results?
Ans. Investment decisions should be based on the stock's current valuation relative to its earnings trajectory, not on a single quarterly result in isolation. The Q1 FY27 numbers (revenue Rs 475.7 Cr, net profit Rs 82.5 Cr) provide the Q1 baseline. Check the P/E and peer comparison on the Univest Screener and consult a SEBI-registered advisor before investing.
Recent Articles

Baroda BNP Paribas Equity Savings Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
3 August 2026

Baroda BNP Paribas Balanced Advantage Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
3 August 2026

Baroda BNP Paribas Yield Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
3 August 2026

Baroda BNP Paribas Business Cycle Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
3 August 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Baroda BNP Paribas Equity Savings Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
Baroda BNP Paribas Balanced Advantage Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
Baroda BNP Paribas Yield Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
Baroda BNP Paribas Business Cycle Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
Baroda BNP Paribas Value Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
Popular this week
Baroda BNP Paribas Equity Savings Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
Baroda BNP Paribas Balanced Advantage Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
Baroda BNP Paribas Yield Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
Baroda BNP Paribas Business Cycle Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026
Baroda BNP Paribas Value Fund Review: Plans, NAV, Returns and Portfolio Analysis 2026

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





